Light Mode
$0.1800 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.1800, $0.0300 below the day’s high of $0.2100
+0.12 (+186.17%) / 6M
Momentum, market sentiment, and recent alerts
HEPA reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +102.2%.
No alerts for HEPA in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.